Cargando…
Development of new therapy for canine mammary cancer with recombinant measles virus
Oncolytic virotherapy is a promising treatment strategy for cancer. We previously generated a recombinant measles virus (rMV-SLAMblind) that selectively uses a poliovirus receptor-related 4 (PVRL4/Nectin4) receptor, but not signaling lymphocyte activation molecule (SLAM). We demonstrated that the vi...
Autores principales: | Shoji, Koichiro, Yoneda, Misako, Fujiyuki, Tomoko, Amagai, Yosuke, Tanaka, Akane, Matsuda, Akira, Ogihara, Kikumi, Naya, Yuko, Ikeda, Fusako, Matsuda, Hiroshi, Sato, Hiroki, Kai, Chieko |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4782952/ https://www.ncbi.nlm.nih.gov/pubmed/27119113 http://dx.doi.org/10.1038/mto.2015.22 |
Ejemplares similares
-
A measles virus selectively blind to signaling lymphocytic activation molecule shows anti-tumor activity against lung cancer cells
por: Fujiyuki, Tomoko, et al.
Publicado: (2015) -
Oncolytic Activity of a Recombinant Measles Virus, Blind to Signaling Lymphocyte Activation Molecule, Against Colorectal Cancer Cells
por: Amagai, Yosuke, et al.
Publicado: (2016) -
Recombinant SLAMblind Measles Virus Is a Promising Candidate for Nectin-4-Positive Triple Negative Breast Cancer Therapy
por: Fujiyuki, Tomoko, et al.
Publicado: (2020) -
Measles virus selectively blind to signaling lymphocyte activity molecule has oncolytic efficacy against nectin‐4‐expressing pancreatic cancer cells
por: Awano, Mutsumi, et al.
Publicado: (2016) -
Immune response elicited in the tumor microenvironment upon rMV‐SLAMblind cancer virotherapy
por: Moritoh, Kanako, et al.
Publicado: (2023)